Epstein–Barr Virus and Multiple Sclerosis: New Data from 2026
In 2026, evidence continues to accumulate that Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS).
This is one of the most important directions of modern medicine, which changes the perception of the nature of this disease.
What research has shown
Large-scale observations based on data from US military personnel demonstrated a clear link between EBV infection and the subsequent development of multiple sclerosis.
- people who did not have EBV had virtually no MS
- after contracting the virus, the risk increased dramatically
- on average, the risk increased more than 30 times
Key conclusion
EBV infection is considered a necessary condition for the development of multiple sclerosis.
At the same time, it is important to understand that most people are infected with EBV, but only a small part of them develop the disease.
What’s new in 2026
Modern research is focused on the mechanisms through which the virus can trigger the pathological process.
The main attention is paid to:
- violation of immune control
- autoimmune reaction
- molecular mimicry
Molecular mimicry means that the immune system begins to perceive its own tissues as foreign due to similarities with viral proteins.
Meaning for medicine
This data opens up new opportunities for:
- prevention (in particular, the development of vaccines against EBV)
- early diagnosis of risks
- new approaches to treatment
Conclusion
Modern science is increasingly considering multiple sclerosis as a disease in the development of which the interaction of the virus and the immune system plays a key role.
This reinforces the importance of herpesvirus research as one of the central directions of future medicine.
Sources
- Harvard T.H. Chan School of Public Health
- U.S. Department of Defense Serum Repository Study
- Science, Nature (updated analyzes 2025–2026)
АС